Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.

Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM.

BMC Cancer. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8.

2.

Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.

Kessous R, Octeau D, Klein K, Tonin PN, Greenwood CMT, Pelmus M, Laskov I, Kogan L, Salvador S, Lau S, Yasmeen A, Gotlieb WH.

Gynecol Oncol. 2018 Mar;148(3):553-558. doi: 10.1016/j.ygyno.2018.01.017. Epub 2018 Feb 1.

PMID:
29395310
3.

Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma.

Rivera B, Di Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, Burk DL, Grapton D, Tomiak E, Hastings V, Hamel N, Wagener R, Aleynikova O, Giroux S, Hamdan FF, Dionne-Laporte A, Zogopoulos G, Rousseau F, Berghuis AM, Provencher D, Rouleau GA, Michaud JL, Mes-Masson AM, Majewski J, Bens S, Siebert R, Narod SA, Akbari MR, Lord CJ, Tonin PN, Orthwein A, Foulkes WD.

Cancer Res. 2017 Aug 15;77(16):4517-4529. doi: 10.1158/0008-5472.CAN-17-0190. Epub 2017 Jun 23.

4.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

5.

Gene Coexpression Analyses Differentiate Networks Associated with Diverse Cancers Harboring TP53 Missense or Null Mutations.

Oros Klein K, Oualkacha K, Lafond MH, Bhatnagar S, Tonin PN, Greenwood CM.

Front Genet. 2016 Aug 3;7:137. doi: 10.3389/fgene.2016.00137. eCollection 2016.

6.

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.

Fleury H, Carmona E, Morin VG, Meunier L, Masson JY, Tonin PN, Provencher D, Mes-Masson AM.

Oncotarget. 2017 Jun 20;8(25):40152-40168. doi: 10.18632/oncotarget.10308.

7.

Corrigendum: Germline RECQL mutations are associated with breast cancer susceptibility.

Cybulski C, Carrot-Zhang J, Kluźniak W, Rivera B, Kashyap A, Wokołorczyk D, Giroux S, Nadaf J, Hamel N, Zhang S, Huzarski T, Gronwald J, Byrski T, Szwiec M, Jakubowska A, Rudnicka H, Lener M, Masojć B, Tonin PN, Rousseau F, Górski B, Dębniak T, Majewski J, Lubiński J, Foulkes WD, Narod SA, Akbari MR.

Nat Genet. 2016 Apr;48(4):473. doi: 10.1038/ng0329-473c. No abstract available.

PMID:
27023777
8.

Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.

Fleury H, Communal L, Carmona E, Portelance L, Arcand SL, Rahimi K, Tonin PN, Provencher D, Mes-Masson AM.

Genes Cancer. 2015 Sep;6(9-10):378-398.

9.

The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.

Légaré S, Cavallone L, Mamo A, Chabot C, Sirois I, Magliocco A, Klimowicz A, Tonin PN, Buchanan M, Keilty D, Hassan S, Laperrière D, Mader S, Aleynikova O, Basik M.

Cancer Res. 2015 Oct 15;75(20):4351-63. doi: 10.1158/0008-5472.CAN-14-3475. Epub 2015 Aug 21.

10.

Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.

Ancot F, Arcand SL, Mes-Masson AM, Provencher DM, Tonin PN.

Oncol Lett. 2015 Jun;9(6):2787-2790. Epub 2015 Apr 20.

11.

Germline TP53 mutational spectrum in French Canadians with breast cancer.

Arcand SL, Akbari MR, Mes-Masson AM, Provencher D, Foulkes WD, Narod SA, Tonin PN.

BMC Med Genet. 2015 Apr 12;16:24. doi: 10.1186/s12881-015-0169-y.

12.

Germline RECQL mutations are associated with breast cancer susceptibility.

Cybulski C, Carrot-Zhang J, Kluźniak W, Rivera B, Kashyap A, Wokołorczyk D, Giroux S, Nadaf J, Hamel N, Zhang S, Huzarski T, Gronwald J, Byrski T, Szwiec M, Jakubowska A, Rudnicka H, Lener M, Masojć B, Tonin PN, Rousseau F, Górski B, Dębniak T, Majewski J, Lubiński J, Foulkes WD, Narod SA, Akbari MR.

Nat Genet. 2015 Jun;47(6):643-6. doi: 10.1038/ng.3284. Epub 2015 Apr 27. Erratum in: Nat Genet. 2016 Apr;48(4):473.

PMID:
25915596
13.

Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.

Gambaro K, Quinn MC, Cáceres-Gorriti KY, Shapiro RS, Provencher D, Rahimi K, Mes-Masson AM, Tonin PN.

BMC Cancer. 2015 Mar 17;15:135. doi: 10.1186/s12885-015-1138-8.

14.

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.

Belanger MH, Dolman L, Arcand SL, Shen Z, Chong G, Mes-Masson AM, Provencher D, Tonin PN.

J Ovarian Res. 2015 Mar 27;8:1. doi: 10.1186/s13048-015-0124-8.

15.

RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer.

Cáceres-Gorriti KY, Carmona E, Barrès V, Rahimi K, Létourneau IJ, Tonin PN, Provencher D, Mes-Masson AM.

PLoS One. 2014 Mar 13;9(3):e91000. doi: 10.1371/journal.pone.0091000. eCollection 2014.

16.

Analysis of genomic abnormalities in tumors: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance.

Oros KK, Arcand SL, Bayani J, Squire JA, Mes-Masson AM, Tonin PN, Greenwood CM.

Cancer Genet. 2013 Apr;206(4):103-15. doi: 10.1016/j.cancergen.2013.03.001. Epub 2013 Apr 25. Review.

PMID:
23623180
17.

Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics.

Gamwell LF, Gambaro K, Merziotis M, Crane C, Arcand SL, Bourada V, Davis C, Squire JA, Huntsman DG, Tonin PN, Vanderhyden BC.

Orphanet J Rare Dis. 2013 Feb 21;8:33. doi: 10.1186/1750-1172-8-33.

18.

VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.

Gambaro K, Quinn MC, Wojnarowicz PM, Arcand SL, de Ladurantaye M, Barrès V, Ripeau JS, Killary AM, Davis EC, Lavoie J, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN.

Mol Oncol. 2013 Jun;7(3):513-30. doi: 10.1016/j.molonc.2012.12.006. Epub 2013 Jan 16.

19.

FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome.

Quinn MC, Wojnarowicz PM, Pickett A, Provencher DM, Mes-Masson AM, Davis EC, Tonin PN.

Int J Oncol. 2013 Mar;42(3):912-20. doi: 10.3892/ijo.2013.1797. Epub 2013 Jan 23.

PMID:
23354471
20.

Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.

Tischkowitz M, Sabbaghian N, Hamel N, Pouchet C, Foulkes WD, Mes-Masson AM, Provencher DM, Tonin PN.

BMC Med Genet. 2013 Jan 9;14:5. doi: 10.1186/1471-2350-14-5.

21.

A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.

Guidugli L, Pankratz VS, Singh N, Thompson J, Erding CA, Engel C, Schmutzler R, Domchek S, Nathanson K, Radice P, Singer C, Tonin PN, Lindor NM, Goldgar DE, Couch FJ.

Cancer Res. 2013 Jan 1;73(1):265-75. doi: 10.1158/0008-5472.CAN-12-2081. Epub 2012 Oct 29.

22.

The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.

Wojnarowicz PM, Oros KK, Quinn MC, Arcand SL, Gambaro K, Madore J, Birch AH, de Ladurantaye M, Rahimi K, Provencher DM, Mes-Masson AM, Greenwood CM, Tonin PN.

PLoS One. 2012;7(9):e45484. doi: 10.1371/journal.pone.0045484. Epub 2012 Sep 20.

23.

Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.

Létourneau IJ, Quinn MC, Wang LL, Portelance L, Caceres KY, Cyr L, Delvoye N, Meunier L, de Ladurantaye M, Shen Z, Arcand SL, Tonin PN, Provencher DM, Mes-Masson AM.

BMC Cancer. 2012 Aug 29;12:379. doi: 10.1186/1471-2407-12-379.

24.

Allelic transcripts dosage effect in morphologically normal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian founder mutation.

Abd-Rabbo D, Abaji C, Cardin GB, Filali-Mouhim A, Arous C, Portelance L, Escobar E, Cloutier S, Tonin PN, Provencher DM, Mes-Masson AM, Maugard CM.

Cancer Prev Res (Phila). 2012 May;5(5):765-77. doi: 10.1158/1940-6207.CAPR-11-0547. Epub 2012 Mar 8.

25.

Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer.

Wojnarowicz PM, Provencher DM, Mes-Masson AM, Tonin PN.

Int J Oncol. 2012 Jun;40(6):1865-80. doi: 10.3892/ijo.2012.1371. Epub 2012 Feb 14.

PMID:
22344671
26.

Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity.

Wojnarowicz P, Gambaro K, de Ladurantaye M, Quinn MC, Provencher D, Mes-Masson AM, Tonin PN.

Oncogenesis. 2012 Sep 10;1:e27. doi: 10.1038/oncsis.2012.25.

27.

Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.

Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, Provencher D, Greenwood CM, Mes-Masson AM, Tonin PN.

PLoS One. 2011;6(12):e28250. doi: 10.1371/journal.pone.0028250. Epub 2011 Dec 6.

28.

The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.

Cote S, Arcand SL, Royer R, Nolet S, Mes-Masson AM, Ghadirian P, Foulkes WD, Tischkowitz M, Narod SA, Provencher D, Tonin PN.

Breast Cancer Res Treat. 2012 Jan;131(1):333-40. doi: 10.1007/s10549-011-1796-4. Epub 2011 Sep 27. Erratum in: Breast Cancer Res Treat. 2012 Jan;131(1):341.

PMID:
21947752
29.

An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer.

Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, Edgren H, Kallioniemi O, Aleynikova O, Przybytkowski E, Malcolm K, Mousses S, Tonin PN, Basik M.

Oncogene. 2012 Apr 19;31(16):2090-100. doi: 10.1038/onc.2011.386. Epub 2011 Sep 5.

PMID:
21892209
30.

An essential role for Ran GTPase in epithelial ovarian cancer cell survival.

Barrès V, Ouellet V, Lafontaine J, Tonin PN, Provencher DM, Mes-Masson AM.

Mol Cancer. 2010 Oct 13;9:272. doi: 10.1186/1476-4598-9-272.

31.

ARID1A mutations in endometriosis-associated ovarian carcinomas.

Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG.

N Engl J Med. 2010 Oct 14;363(16):1532-43. doi: 10.1056/NEJMoa1008433. Epub 2010 Sep 8.

32.

Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.

Cavallone L, Arcand SL, Maugard CM, Nolet S, Gaboury LA, Mes-Masson AM, Ghadirian P, Provencher D, Tonin PN.

Fam Cancer. 2010 Dec;9(4):507-17. doi: 10.1007/s10689-010-9372-3.

PMID:
20694749
33.

Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model.

Meunier L, Puiffe ML, Le Page C, Filali-Mouhim A, Chevrette M, Tonin PN, Provencher DM, Mes-Masson AM.

Transl Oncol. 2010 Aug 1;3(4):230-8.

34.

Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations.

Hosein AN, Wu M, Arcand SL, Lavallée S, Hébert J, Tonin PN, Basik M.

Cancer Res. 2010 Jul 15;70(14):5770-7. doi: 10.1158/0008-5472.CAN-10-0673. Epub 2010 Jun 22.

35.

Protease inhibitor SERPINA1 expression in epithelial ovarian cancer.

Normandin K, Péant B, Le Page C, de Ladurantaye M, Ouellet V, Tonin PN, Provencher DM, Mes-Masson AM.

Clin Exp Metastasis. 2010;27(1):55-69. doi: 10.1007/s10585-009-9303-6. Epub 2010 Jan 5.

PMID:
20049513
36.

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.

Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, Huntsman D, Provencher DM, Mes-Masson AM.

J Pathol. 2010 Feb;220(3):392-400. doi: 10.1002/path.2659.

PMID:
19967725
37.

The chemiluminescence based Ziplex automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip expression profiles.

Quinn MC, Wilson DJ, Young F, Dempsey AA, Arcand SL, Birch AH, Wojnarowicz PM, Provencher D, Mes-Masson AM, Englert D, Tonin PN.

J Transl Med. 2009 Jul 6;7:55. doi: 10.1186/1479-5876-7-55.

38.

Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer.

Manderson EN, Birch AH, Shen Z, Mes-Masson AM, Provencher D, Tonin PN.

Int J Gynecol Cancer. 2009 May;19(4):513-25. doi: 10.1111/IGC.0b013e3181a3cd38.

PMID:
19509545
39.

Thematic issue on the molecular biology of hereditary ovarian cancer. Preface.

Tonin PN.

Mol Oncol. 2009 Apr;3(2):94-6. doi: 10.1016/j.molonc.2009.02.002. Epub 2009 Feb 14. No abstract available.

40.

BMP-2 signaling in ovarian cancer and its association with poor prognosis.

Le Page C, Puiffe ML, Meunier L, Zietarska M, de Ladurantaye M, Tonin PN, Provencher D, Mes-Masson AM.

J Ovarian Res. 2009 Apr 14;2:4. doi: 10.1186/1757-2215-2-4.

41.

Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer.

Cody NA, Shen Z, Ripeau JS, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN.

Mol Carcinog. 2009 Dec;48(12):1077-92. doi: 10.1002/mc.20535.

PMID:
19347865
42.

Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer.

Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN.

Mol Carcinog. 2009 Jul;48(7):648-61. doi: 10.1002/mc.20511.

PMID:
19123201
43.

Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.

Ouellet V, Ling TH, Normandin K, Madore J, Lussier C, Barrès V, Bachvarov D, Rancourt C, Tonin PN, Provencher DM, Mes-Masson AM.

BMC Cancer. 2008 Nov 26;8:346. doi: 10.1186/1471-2407-8-346.

44.

Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.

Novak DJ, Chen LQ, Ghadirian P, Hamel N, Zhang P, Rossiny V, Cardinal G, Robidoux A, Tonin PN, Rousseau F, Narod SA, Foulkes WD.

BMC Cancer. 2008 Aug 15;8:239. doi: 10.1186/1471-2407-8-239.

45.

Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines.

Cody NA, Zietarska M, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN.

BMC Med Genomics. 2008 Aug 7;1:34. doi: 10.1186/1755-8794-1-34.

46.

Characterization of three new serous epithelial ovarian cancer cell lines.

Ouellet V, Zietarska M, Portelance L, Lafontaine J, Madore J, Puiffe ML, Arcand SL, Shen Z, Hébert J, Tonin PN, Provencher DM, Mes-Masson AM.

BMC Cancer. 2008 May 28;8:152. doi: 10.1186/1471-2407-8-152.

47.

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.

Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN.

BMC Cancer. 2008 Apr 10;8:96. doi: 10.1186/1471-2407-8-96.

48.

BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.

Le Page C, Ouellet V, Quinn MC, Tonin PN, Provencher DM, Mes-Masson AM.

Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):913-20. doi: 10.1158/1055-9965.EPI-07-0692.

49.

Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes.

Wojnarowicz PM, Breznan A, Arcand SL, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN.

Int J Gynecol Cancer. 2008 Sep-Oct;18(5):963-75. Epub 2007 Nov 20.

PMID:
18028382
50.

Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer.

Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson AM.

Neoplasia. 2007 Oct;9(10):820-9.

Supplemental Content

Loading ...
Support Center